BioCentury
ARTICLE | Clinical News

Celldex data show Rintega's OS benefit

November 21, 2015 1:38 AM UTC

Celldex Therapeutics Inc. (NASDAQ:CLDX) gained $1.68 (12%) to $16.19 on Friday after it announced 24-month survival data from the Phase II ReACT study of Rintega rindopepimut to treat EGFR variant III ( EGFRvIII)-positive recurrent glioblastoma multiforme (GBM).

Celldex said Rintega plus Avastin bevacizumab significantly improved long term survival over Avastin alone in the intent-to-treat population (HR=0.53, p=0.0137). Rintega-treated patients had a 25% two-year survival rate, compared to 0% for control. ...